To conclude, we have for the first time successfully generated a scFv phage library from HIV-1 subtype C chronically infected antiretroviral naïve children. From this library, we identified 2B10 as a cross-neutralizing CD4bs directed scFv monoclonal with reasonable breadth and potency, demonstrating neutralizing activity against tier 1, 2, and 3 viruses, including viruses of both adult and pediatric origin. Such anti-HIV-1 human scFvs, are potential candidates for conferring passive protection. Moreover, a combination of scFvs with antiretroviral drugs can be an effective strategy to suppress viremia at an early stage and thus block HIV-1 infection in children, mainly acquiring infection by vertical transmission.